Active Filter(s):
Details:
BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells.
Lead Product(s): BRTX-100
Therapeutic Area: Musculoskeletal Product Name: BRTX-100
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Biorestorative Therapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 05, 2022